Kevin DeGeeter Analyst PerformanceManaging Director, Equity Research at LADENBURG THALM/SH SHKevin DeGeeter is a stock analyst at LADENBURG THALM/SH SH in the medical sector, covering 20 publicly traded companies. Over the past year, Kevin DeGeeter has issued 5 stock ratings, including and buy recommendations. While full access to Kevin DeGeeter's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kevin DeGeeter's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings49 Last 10 YearsBuy Recommendations95.83% 46 Buy RatingsCompanies Covered20 Unique Companies Ratings Distribution48RatingsDistribution of strong buy, buy, hold, and sell ratings by Kevin DeGeeter.RatingPercentageCount Strong Buy0.0%0 ratings Buy95.8%46 ratings Hold4.2%2 ratings Sell0.0%0 ratingsOut of 48 total stock ratings issued by Kevin DeGeeter at LADENBURG THALM/SH SH, the majority (95.8%) have been Buy recommendations, followed by 4.2% Hold.Best & Worst CallsBest Call0000.0%BNGOAug 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ORICJun 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ95.0% of companies on NASDAQ19 companiesNYSE5.0% of companies on NYSE1 companyKevin DeGeeter, an analyst at LADENBURG THALM/SH SH, currently covers 20 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical20 companies100.0%Kevin DeGeeter of LADENBURG THALM/SH SH specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE11 companies55.0%MED - DRUGS3 companies15.0%MED PRODUCTS1 company5.0%MEDICAL INFO SYS1 company5.0%MED - GENERIC DRG1 company5.0%MEDICAL LABORATORIES1 company5.0%PHARMACEUTICAL PREPARATIONS1 company5.0%MED INSTRUMENTS1 company5.0% About Kevin DeGeeterKevin DeGeeter has rejoined Ladenburg Thalmann as a Managing Director in our Equity Research department, effective June 2025. In this role, Kevin will lead equity research coverage of oncology, infectious disease, and cell therapy companies, focusing on businesses with market capitalizations ranging from $50 million to $5 billion. Kevin brings over 20 years of experience in both buyside and sell side research, with a strong track record in biotechnology and molecular diagnostics. Prior to rejoining Ladenburg Thalmann, he was an Analyst at Oppenheimer & Co., where he covered small-cap molecular diagnostics and biotech stocks. His career also includes roles at J.P. Morgan, PaineWebber, Natexis Bleichroeder, and Manning & Napier Advisors. In addition to his research credentials, Kevin served as CFO of Nabsys, a life science tools company that was later acquired by Hitachi Ltd. Kevin holds a BA in Economics from Colgate University.Follow on LinkedIn Kevin DeGeeter's Ratings History at LADENBURG THALM/SH SH Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCLRBCellectar Biosciences5/15/2026Initiated Coverage$3.20Buy$0.0000.00% ROINXTCNextCure11/7/2025Upgrade$9.82$18.00Buy$0.0000.00% ROINVCRNovoCure7/8/2025Initiated Coverage$16.89$30.00Buy$0.0000.00% ROICRDFCardiff Oncology7/8/2025Initiated Coverage$3.65$19.00Buy$0.0000.00% ROIORICOric Pharmaceuticals7/8/2025Initiated Coverage$10.65$15.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
